EVLO Stock Price, Evelo Biosciences Inc Quote, Chart

Market Summary

USD0.050.00

Market Closed

0.00%

EVLO Stock Price

View Fullscreen

EVLO RSI Chart

EVLO Valuation

Market Cap

946.5K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.72

EV/EBITDA

0.22

Price/Free Cashflow

-0.01

EVLO Price/Sales (Trailing)

EVLO Profitability

EBT Margin

-7763.97%

Return on Equity

-14.67%

Return on Assets

-399.23%

Free Cashflow Yield

-7.8K%

EVLO Fundamentals

EVLO Revenue

Revenue (TTM)

1.0M

EVLO Earnings

Earnings (TTM)

-82.3M

Earnings Growth (Yr)

59.55%

Earnings Growth (Qtr)

41.41%

Breaking Down EVLO Revenue

Last 90 days

25%

Trailing 12 Months

-98.0%

How does EVLO drawdown profile look like?

EVLO Financial Health

Current Ratio

0.48

EVLO Investor Care

Shares Dilution (1Y)

245.41%

Diluted EPS (TTM)

-11.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	2.0M	2.1M	1.6M	1.0M
2018	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Evelo Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 08, 2023	mchale duncan	sold	-1,023	0.33	-3,103	chief medical officer
Nov 08, 2023	thorell marella	sold	-597	0.33	-1,811	chief financial officer
Nov 08, 2023	gill simba	sold	-56.76	0.33	-172	president & ceo
Nov 08, 2023	bodmer mark	sold	-1,043	0.33	-3,163	cso, president of r&d
Nov 07, 2023	thorell marella	acquired	-	-	6,500	chief financial officer
Nov 07, 2023	gill simba	acquired	-	-	1,172	president & ceo
Nov 07, 2023	bodmer mark	acquired	-	-	6,625	cso, president of r&d
Nov 07, 2023	mchale duncan	acquired	-	-	6,500	chief medical officer
Nov 02, 2023	bodmer mark	sold	-2,261	0.33	-6,854	cso, president of r&d
Nov 02, 2023	mchale duncan	sold	-2,261	0.33	-6,854	chief medical officer

Which funds bought or sold EVLO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-706	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-1,402,230	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-46,000	-	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-63.00	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-10,933	-	-%
Feb 14, 2024	Alyeska Investment Group, L.P.	sold off	-100	-1,039,200	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-104,582	-	-%
Feb 14, 2024	Flagship Pioneering Inc.	sold off	-100	-31,095,900	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-149,325	-	-%
Feb 14, 2024	HarbourVest Partners LLC	sold off	-100	-5,691,350	-	-%

Are Funds Buying or Selling EVLO?

Are funds buying EVLO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EVLO

No. of Funds

Unveiling Evelo Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Aug 10, 2023	fmr llc	-	0	SC 13G
Jul 21, 2023	harbourvest partners l.p.	8.8%	1,451,876	SC 13G
Jul 21, 2023	horizon technology finance corp	11.5%	2,164,502	SC 13G
Jul 13, 2023	flagship ventures fund v, l.p.	0.2%	34,219	SC 13D/A
Jul 10, 2023	fmr llc	-	0	SC 13G/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
Feb 21, 2023	dnca finance	4.96%	5	SC 13D/A
Feb 14, 2023	harbourvest partners l.p.	2.8%	3,063,505	SC 13G/A

Recent SEC filings of Evelo Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Mar 08, 2024	EFFECT	EFFECT
Jan 26, 2024	S-8 POS	Employee Benefits Plan
Jan 26, 2024	S-8 POS	Employee Benefits Plan
Jan 26, 2024	POS AM	POS AM
Jan 26, 2024	8-K	Current Report
Jan 26, 2024	15-12G	15-12G

Peers (Alternatives to Evelo Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Evelo Biosciences Inc News

Latest updates

Evelo Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)								(In Millions)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-79.0%	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00
Operating Expenses	5.5%	23.00	21.00	21.00	21.00	16.00	16.00	15.00	10.00
S&GA Expenses	6.9%	6.00	6.00	6.00	5.00	5.00	5.00	5.00	3.00
R&D Expenses	4.9%	16.00	16.00	15.00	16.00	11.00	11.00	10.00	7.00
Interest Expenses	50.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	-	0.00	-	-	-	-	-	-	-
Earnings Before Taxes	-3.6%	-22.41	-21.63	-20.94	-20.30	-	-	-	-
Net Income	-4.5%	-22.60	-21.63	-20.94	-20.30	-15.44	-15.86	-15.15	-10.50

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-0.9%	21.00	21.00	42.00	64.00	86.00	112	59.00	88.00	116	145	153	91.00	105	114	83.00	91.00	111	126	142	160	176
Current Assets	68.1%	19.00	11.00	30.00	52.00	72.00	97.00	43.00	71.00	98.00	126	134	71.00	85.00	93.00	61.00	81.00	101	117	133	152	168
Cash Equivalents	126.5%	17.00	8.00	27.00	48.00	69.00	92.00	40.00	70.00	96.00	125	126	70.00	83.00	92.00	60.00	79.00	99.00	111	107	94.00	81.00
Net PPE	-62.3%	1.00	2.00	4.00	5.00	5.00	6.00	6.00	7.00	8.00	8.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	7.00	6.00
Liabilities	-29.3%	47.00	67.00	69.00	69.00	77.00	76.00	76.00	79.00	83.00	83.00	65.00	60.00	54.00	45.00	44.00	31.00	31.00	26.00	23.00	23.00	25.00
Current Liabilities	-28.4%	40.00	56.00	57.00	12.00	27.00	21.00	16.00	17.00	21.00	20.00	19.00	20.00	14.00	14.00	12.00	10.00	10.00	10.00	11.00	9.00	9.00
Long Term Debt	-	-	-	-	44.00	37.00	41.00	45.00	47.00	47.00	46.00	29.00	30.00	30.00	20.00	20.00	20.00	20.00	15.00	10.00	12.00	14.00
LT Debt, Current	-22.7%	34.00	44.00	44.00	-	10.00	6.00	2.00	-	-	-	1.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	44.00	37.00	41.00	45.00	47.00	47.00	46.00	29.00	30.00	30.00	20.00	20.00	20.00	20.00	15.00	10.00	12.00	14.00
Shareholder's Equity	-	-	-	-	-	9.00	36.00	-	9.00	33.00	62.00	88.00	30.00	50.00	69.00	39.00	60.00	81.00	100	119	137	151
Retained Earnings	-2.1%	-588	-575	-554	-529	-505	-475	-444	-414	-386	-352	-320	-292	-263	-242	-221	-198	-176	-154	-133	-113	-97.94
Additional Paid-In Capital	6.0%	561	530	527	524	515	511	428	423	419	414	409	323	314	312	261	259	257	255	253	250	249
Shares Outstanding	236.7%	19.00	6.00	6.00	6.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	120	-	-	-	414	-	-	-	113	-	-	-	123	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	47.5%	-10,408	-19,827	-20,276	-23,190	-22,587	-26,526	-28,932	-27,846	-27,167	-15,432	-26,280	-18,953	-18,219	-16,376	-19,515	-18,994	-19,637	-15,356	-17,993	-15,456	-12,660
Share Based Compensation	33.3%	1,200	900	2,909	6,902	200	300	4,275	4,369	4,441	3,772	3,264	2,375	2,045	2,093	1,955	2,015	2,062	2,135	1,953	1,565	1,595
Cashflow From Investing	-	513	-	-12.00	-228	-9.00	-232	-153	475	-809	-833	-314	-409	-261	-216	-429	-463	2,913	19,396	30,124	28,581	-86,046
Cashflow From Financing	-	19,220	-	-199	1,739	665	79,134	117	-126	331	15,007	82,328	6,702	9,887	48,650	226	229	4,560	-55.00	258	18.00	-488

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EVLO Income Statement

2023-09-30

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 6,499	$ 21,928	$ 37,399	$ 62,470
General and administrative	3,891	7,126	15,849	24,909
Loss on disposal and impairment of property and equipment	793	0	2,409	0
Total operating expenses	11,183	29,054	55,657	87,379
Loss from operations	(11,183)	(29,054)	(55,657)	(87,379)
Other income (expense):
Interest expense, net	(1,162)	(788)	(3,642)	(2,835)
Change in fair value of warrants	(9)	0	622	0
Other miscellaneous income (expense), net	(27)	(615)	230	(386)
Total other expenses, net	(1,198)	(1,403)	(2,790)	(3,221)
Loss before income taxes	(12,381)	(30,457)	(58,447)	(90,600)
Income tax benefit (expense)	17	(107)	(361)	(386)
Net loss	$ (12,364)	$ (30,564)	$ (58,808)	$ (90,986)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.71)	$ (5.66)	$ (6.16)	$ (22.88)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.71)	$ (5.66)	$ (6.16)	$ (22.88)
Weighted average number of common shares outstanding, basic (in shares)	17,384,243	5,402,592	9,546,129	3,976,438
Weighted average number of common shares outstanding, diluted (in shares)	17,384,243	5,402,592	9,546,129	3,976,438

EVLO Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,262	$ 47,940
Prepaid expenses and other current assets	1,674	3,633
Total current assets	18,936	51,573
Property and equipment, net	894	4,842
Right of use asset - operating lease	0	6,868
Other assets	797	1,158
Total assets	20,627	64,441
Current liabilities:
Debt, current portion	33,948	0
Accounts payable	526	1,764
Accrued expenses	4,550	7,945
Operating lease liability, current portion	0	2,259
Other current liabilities	737	427
Total current liabilities	39,761	12,395
Noncurrent liabilities:
Debt, net of current portion	0	43,614
Operating lease liability, net of current portion	0	5,265
Deferred revenue	7,500	7,500
Other noncurrent liabilities	73	659
Total liabilities	47,334	69,433
Commitments and contingencies (Note 9)
Stockholder’s deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized; 18,853,587 and 5,542,637 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	19	6
Additional paid-in capital	561,304	524,224
Accumulated deficit	(588,030)	(529,222)
Total stockholders’ deficit	(26,707)	(4,992)
Total liabilities and stockholders’ deficit	$ 20,627	$ 64,441

About Evelo Biosciences Inc

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Balkrishan Gill Ph.D.
WEBSITE	evelobio.com
INDUSTRY	Biotechnology
EMPLOYEES	66

Evelo Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Evelo Biosciences Inc? What does EVLO stand for in stocks?

EVLO is the stock ticker symbol of Evelo Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evelo Biosciences Inc (EVLO)?

As of Thu May 02 2024, market cap of Evelo Biosciences Inc is 946.55 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EVLO stock?

You can check EVLO's fair value in chart for subscribers.

What is the fair value of EVLO stock?

You can check EVLO's fair value in chart for subscribers. The fair value of Evelo Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evelo Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EVLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evelo Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether EVLO is over valued or under valued. Whether Evelo Biosciences Inc is cheap or expensive depends on the assumptions which impact Evelo Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVLO.

What is Evelo Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, EVLO's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVLO PE ratio will change depending on the future growth rate expectations of investors.